Literature DB >> 22246237

Increased PARP-1 association with DNA in alkylation damaged, PARP-inhibited mouse fibroblasts.

Padmini S Kedar1, Donna F Stefanick, Julie K Horton, Samuel H Wilson.   

Abstract

Treatment of base excision repair-proficient mouse fibroblasts with the DNA alkylating agent methyl methanesulfonate (MMS) and a small molecule inhibitor of PARP-1 results in a striking cell killing phenotype, as previously reported. Earlier studies showed that the mechanism of cell death is apoptosis and requires DNA replication, expression of PARP-1, and an intact S-phase checkpoint cell signaling system. It is proposed that activity-inhibited PARP-1 becomes immobilized at DNA repair intermediates, and that this blocks DNA repair and interferes with DNA replication, eventually promoting an S-phase checkpoint and G(2)-M block. Here we report studies designed to evaluate the prediction that inhibited PARP-1 remains DNA associated in cells undergoing repair of alkylation-induced damage. Using chromatin immunoprecipitation with anti-PARP-1 antibody and qPCR for DNA quantification, a higher level of DNA was found associated with PARP-1 in cells treated with MMS plus PARP inhibitor than in cells without inhibitor treatment. These results have implications for explaining the extreme hypersensitivity phenotype after combination treatment with MMS and a PARP inhibitor.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22246237      PMCID: PMC3307909          DOI: 10.1158/1541-7786.MCR-11-0477

Source DB:  PubMed          Journal:  Mol Cancer Res        ISSN: 1541-7786            Impact factor:   5.852


  42 in total

1.  IsoFinder: computational prediction of isochores in genome sequences.

Authors:  José L Oliver; Pedro Carpena; Michael Hackenberg; Pedro Bernaola-Galván
Journal:  Nucleic Acids Res       Date:  2004-07-01       Impact factor: 16.971

2.  A compact view of isochores in the draft human genome sequence.

Authors:  Adam Pavlícek; Jan Paces; Oliver Clay; Giorgio Bernardi
Journal:  FEBS Lett       Date:  2002-01-30       Impact factor: 4.124

Review 3.  Evolution of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. From concept to clinic.

Authors:  Dana V Ferraris
Journal:  J Med Chem       Date:  2010-06-24       Impact factor: 7.446

4.  Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by ATP depletion.

Authors:  H C Ha; S H Snyder
Journal:  Proc Natl Acad Sci U S A       Date:  1999-11-23       Impact factor: 11.205

Review 5.  XRCC1 and DNA polymerase beta in cellular protection against cytotoxic DNA single-strand breaks.

Authors:  Julie K Horton; Mary Watson; Donna F Stefanick; Daniel T Shaughnessy; Jack A Taylor; Samuel H Wilson
Journal:  Cell Res       Date:  2008-01       Impact factor: 25.617

6.  Potentiation of temozolomide cytotoxicity by poly(ADP)ribose polymerase inhibitor ABT-888 requires a conversion of single-stranded DNA damages to double-stranded DNA breaks.

Authors:  Xuesong Liu; Yan Shi; Ran Guan; Cherrie Donawho; Yanping Luo; Joann Palma; Gui-Dong Zhu; Eric F Johnson; Luis E Rodriguez; Nayereh Ghoreishi-Haack; Ken Jarvis; Vincent P Hradil; Milagros Colon-Lopez; Bryan F Cox; Vered Klinghofer; Thomas Penning; Saul H Rosenberg; David Frost; Vincent L Giranda; Yan Luo
Journal:  Mol Cancer Res       Date:  2008-10       Impact factor: 5.852

Review 7.  DNA repair proteins as molecular targets for cancer therapeutics.

Authors:  Mark R Kelley; Melissa L Fishel
Journal:  Anticancer Agents Med Chem       Date:  2008-05       Impact factor: 2.505

8.  Purification, sequencing, and molecular identification of a mammalian PP-InsP5 kinase that is activated when cells are exposed to hyperosmotic stress.

Authors:  Jae H Choi; Jason Williams; Jaiesoon Cho; J R Falck; Stephen B Shears
Journal:  J Biol Chem       Date:  2007-08-16       Impact factor: 5.157

9.  Relationships between replication timing and GC content of cancer-related genes on human chromosomes 11q and 21q.

Authors:  Yoshihisa Watanabe; Takashi Abe; Toshimichi Ikemura; Masato Maekawa
Journal:  Gene       Date:  2008-12-14       Impact factor: 3.688

10.  Direct interaction between mammalian DNA polymerase beta and proliferating cell nuclear antigen.

Authors:  Padmini S Kedar; Soon-Jong Kim; Anthony Robertson; Esther Hou; Rajendra Prasad; Julie K Horton; Samuel H Wilson
Journal:  J Biol Chem       Date:  2002-06-12       Impact factor: 5.157

View more
  24 in total

Review 1.  Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.

Authors:  Spyridon P Basourakos; Likun Li; Ana M Aparicio; Paul G Corn; Jeri Kim; Timothy C Thompson
Journal:  Curr Med Chem       Date:  2017       Impact factor: 4.530

2.  HMGN1 protein regulates poly(ADP-ribose) polymerase-1 (PARP-1) self-PARylation in mouse fibroblasts.

Authors:  Aya Masaoka; Natalie R Gassman; Padmini S Kedar; Rajendra Prasad; Esther W Hou; Julie K Horton; Michael Bustin; Samuel H Wilson
Journal:  J Biol Chem       Date:  2012-06-26       Impact factor: 5.157

3.  Inter-individual variation in DNA repair capacity: a need for multi-pathway functional assays to promote translational DNA repair research.

Authors:  Zachary D Nagel; Isaac A Chaim; Leona D Samson
Journal:  DNA Repair (Amst)       Date:  2014-04-26

4.  Randomized Trial of Oral Cyclophosphamide and Veliparib in High-Grade Serous Ovarian, Primary Peritoneal, or Fallopian Tube Cancers, or BRCA-Mutant Ovarian Cancer.

Authors:  Shivaani Kummar; Amit M Oza; Gini F Fleming; Daniel M Sullivan; David R Gandara; Michael J Naughton; Miguel A Villalona-Calero; Robert J Morgan; Peter M Szabo; Ahrim Youn; Alice P Chen; Jiuping Ji; Deborah E Allen; Chih-Jian Lih; Michele G Mehaffey; William D Walsh; Paul M McGregor; Seth M Steinberg; P Mickey Williams; Robert J Kinders; Barbara A Conley; Richard M Simon; James H Doroshow
Journal:  Clin Cancer Res       Date:  2015-01-14       Impact factor: 12.531

5.  Repair pathway for PARP-1 DNA-protein crosslinks.

Authors:  Rajendra Prasad; Julie K Horton; Da-Peng Dai; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2018-11-12

Review 6.  Requirements for PARP-1 covalent crosslinking to DNA (PARP-1 DPC).

Authors:  Rajendra Prasad; Julie K Horton; Samuel H Wilson
Journal:  DNA Repair (Amst)       Date:  2020-04-28

7.  Synergistic activity of PARP inhibition by talazoparib (BMN 673) with temozolomide in pediatric cancer models in the pediatric preclinical testing program.

Authors:  Malcolm A Smith; C Patrick Reynolds; Min H Kang; E Anders Kolb; Richard Gorlick; Hernan Carol; Richard B Lock; Stephen T Keir; John M Maris; Catherine A Billups; Dmitry Lyalin; Raushan T Kurmasheva; Peter J Houghton
Journal:  Clin Cancer Res       Date:  2014-12-10       Impact factor: 12.531

8.  Rationale for poly(ADP-ribose) polymerase (PARP) inhibitors in combination therapy with camptothecins or temozolomide based on PARP trapping versus catalytic inhibition.

Authors:  Junko Murai; Yiping Zhang; Joel Morris; Jiuping Ji; Shunichi Takeda; James H Doroshow; Yves Pommier
Journal:  J Pharmacol Exp Ther       Date:  2014-03-20       Impact factor: 4.030

Review 9.  Therapeutic applications of PARP inhibitors: anticancer therapy and beyond.

Authors:  Nicola J Curtin; Csaba Szabo
Journal:  Mol Aspects Med       Date:  2013-01-29

10.  Aag DNA glycosylase promotes alkylation-induced tissue damage mediated by Parp1.

Authors:  Jennifer A Calvo; Catherine A Moroski-Erkul; Annabelle Lake; Lindsey W Eichinger; Dharini Shah; Iny Jhun; Prajit Limsirichai; Roderick T Bronson; David C Christiani; Lisiane B Meira; Leona D Samson
Journal:  PLoS Genet       Date:  2013-04-04       Impact factor: 5.917

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.